Complete remission of primary bilateral adrenal lymphoma achieved by Rituximab-CHOP chemotherapy

  • Yin-long Yang
  • Ting-ting Ye
  • Zhu-yin Wang
  • Er-li Gao
  • Lei-ping Wang
  • Peng Li
  • Xue-min Chen
  • Xiao-hua Zhang
Case Report


Primary adrenal lymphoma (PAL) is an exceedingly rare disease. Because of its rareness, uncertain etiology, variable duration of survival, unremarkable clinical presentations and unsatisfied therapeutic strategies, its treatment has always been unsatisfactory. Here we report a 50-year-old male patient with primary bilateral adrenal diffuse large B-cell lymphoma. He was treated with surgery followed by combined chemotherapy using R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). He achieved complete remission after 3 cycles of chemotherapy. At present, he is considered free of tumor at 3 years after chemotherapy. Our case report demonstrates that patients with primary bilateral adrenal diffuse large B-cell lymphoma may achieve a good outcome using R-CHOP chemotherapy. To the best of our knowledge, our patient who achieved complete remission after R-CHOP chemotherapy has had the longest survival as published in the literature.


Primary adrenal lymphoma Non-Hodgkin lymphoma R-CHOP Complete Remission 


  1. [1]
    Ozimek A, Diebold J, Linke R, et al. Bilateral primary adrenal non-Hodgkin’s lymphoma and primary adrenocortical carcinoma—review of the literature preoperative differentiation of adrenal tumors. Endocr J 2008;55: 625–638PubMedCrossRefGoogle Scholar
  2. [2]
    Wang JP, Sun HR, Li YJ, et al. Imaging features of primary adrenal lymphoma. Chin Med J (Engl) 2009;122: 2516–2520Google Scholar
  3. [3]
    Nishiuchi T, Imachi H, Fujiwara M, et al. A case of non-Hodgkin’s lymphoma primary arising in both adrenal glands associated with adrenal failure. Endocrine 2009;35: 34–37PubMedCrossRefGoogle Scholar
  4. [4]
    Mantzios G, Tsirigotis P, Veliou F, et al. Primary adrenal lymphoma presenting as Addison’s disease: case report and review of the literature. Ann Hematol 2004;83:460–463PubMedCrossRefGoogle Scholar
  5. [5]
    Kumar R, Xiu Y, Mavi A, et al. FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature. Clin Nucl Med 2005;30: 222–230PubMedCrossRefGoogle Scholar
  6. [6]
    Tomoyose T, Nagasaki A, Uchihara JN, et al. Primary adrenal adult T-cell leukemia/lymphoma: a case report and review of the literature. Am J Hematol 2007;82: 748–752PubMedCrossRefGoogle Scholar
  7. [7]
    Alvarez-Castells A, Pedraza S, Tallada N, et al. CT of primary bilateral adrenal lymphoma. J Comput Assist Tomogr 1993;17: 408–409PubMedCrossRefGoogle Scholar
  8. [8]
    Serrano S, Tejedor L, Garcia B, et al. Addisonian crisis as the presenting feature of bilateral primary adrenal lymphoma. Cancer 1993;71: 4030–4033PubMedCrossRefGoogle Scholar
  9. [9]
    Grigg AP, Connors JM. Primary adrenal lymphoma. Clin Lymphoma 2003;4: 154–160PubMedCrossRefGoogle Scholar
  10. [10]
    Mori M, Kitamura K, Masuda M, et al. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THPCOPE regimens in elderly patients with non-Hodgkin’s lymphoma. Int J Hematol 2005;81:246–254PubMedCrossRefGoogle Scholar
  11. [11]
    Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70:1445–1476PubMedCrossRefGoogle Scholar
  12. [12]
    Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391PubMedCrossRefGoogle Scholar
  13. [13]
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235–242PubMedCrossRefGoogle Scholar
  14. [14]
    Colovic N, Jurisic V, Terzic T, et al. Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin’s lymphoma. Arch Dermatol Res 2009;301:689–692PubMedCrossRefGoogle Scholar
  15. [15]
    Shirao S, Kuroda H, Kida M, et al. [Effective combined modality therapy for a patient with primary adrenal lymphoma]. Rinsho Ketsueki 2006;47: 204–209PubMedGoogle Scholar
  16. [16]
    Kim KM, Yoon DH, Lee SG, et al. A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy. J Korean Med Sci 2009;24: 525–528PubMedCrossRefGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Yin-long Yang
    • 1
  • Ting-ting Ye
    • 2
  • Zhu-yin Wang
    • 3
  • Er-li Gao
    • 1
  • Lei-ping Wang
    • 4
  • Peng Li
    • 5
  • Xue-min Chen
    • 1
  • Xiao-hua Zhang
    • 1
  1. 1.Department of OncologyThe First Affiliated Hospital of Wenzhou Medical CollegeWenzhouZhejiang Province, China
  2. 2.Department of EndocrinologyThe First Affiliated Hospital of Wenzhou Medical CollegeWenzhouZhejiang Province, China
  3. 3.Department of Medicine, The First Clinical Medical Institute of Wenzhou Medical CollegeThe First Affiliated Hospital of Wenzhou Medical CollegeWenzhouZhejiang Province, China
  4. 4.Department of Medical Oncology, Cancer HospitalFudan UniversityShanghaiChina
  5. 5.Department of PathologyThe First Affiliated Hospital of Wenzhou Medical CollegeWenzhouZhejiang Province, China

Personalised recommendations